Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction

Area of Science:

• Cardiovascular Research
• Myocardial Infarction Therapeutics
• Matrix Metalloproteinase Inhibition

Background:

• Broad matrix metalloproteinase (MMP) inhibition is known to attenuate left ventricular remodeling post-myocardial infarction (MI).
• The efficacy of selective MMP inhibition and its impact on angiogenesis after MI remain unclear.

Purpose of the Study:

• To investigate the effects of a selective MMP inhibitor on left ventricular remodeling and angiogenesis after MI in a rabbit model.
• To determine if selective MMP inhibition, which spares MMP-1, can prevent adverse cardiac remodeling and influence neovascularization.

Main Methods:

• A selective MMP inhibitor (MMPi), not inhibiting MMP-1 (a major collagenase in rabbits and humans), was administered to rabbits post-MI.
• Rabbits were randomized to receive either MMPi or vehicle, with assessments conducted at 4 weeks post-MI.
• Evaluated parameters included infarct size, collagen content, ventricular dimensions, infarct wall thickness, and neovascularization.

Main Results:

• Selective MMP inhibition significantly reduced ventricular dilation and infarct wall thinning compared to vehicle.
• No significant differences were observed in infarct size or collagen fractional area between groups.
• MMPi treatment led to a marked increase in capillary and arteriole density within the subendocardial layer of the infarct.

Conclusions:

• Selective MMP inhibition effectively attenuates left ventricular remodeling post-MI, even without inhibiting MMP-1.
• This approach appears to enhance, rather than impede, neovascularization in the infarct zone.
• Selective MMP inhibition represents a promising therapeutic strategy for post-MI cardiac repair.